New hope for young cancer patients: drug combo targets relapsed solid tumors

NCT ID NCT06761417

Recruiting now Disease control Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

First seen May 14, 2026 · Last updated Jun 18, 2026 · Updated 5 times

Summary

This study tests a combination of drugs (liposomal mitoxantrone, capecitabine, and anlotinib) in children, adolescents, and young adults whose solid tumors have returned or not responded to previous treatments. The goal is to see if this regimen can shrink tumors or stop them from growing. Participants will receive up to 6 cycles of treatment and be closely monitored for side effects and tumor response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHILDREN are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Cancer Hospital, Chinese Academy of Medical Sciences
RECRUITING

Beijing, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

connective and soft tissue neoplasm neuroblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADOLESCENTS CHILDREN SOLID TUMORS